Orion Porfolio Solutions LLC Buys 9,037 Shares of Johnson & Johnson $JNJ

Orion Porfolio Solutions LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 212,806 shares of the company’s stock after buying an additional 9,037 shares during the quarter. Orion Porfolio Solutions LLC’s holdings in Johnson & Johnson were worth $32,506,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Semmax Financial Advisors Inc. boosted its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares in the last quarter. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter worth $35,000. 1248 Management LLC purchased a new position in Johnson & Johnson during the 1st quarter worth $48,000. Vermillion & White Wealth Management Group LLC increased its position in Johnson & Johnson by 66.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after buying an additional 150 shares in the last quarter. Finally, Gladwyn Financial Advisors Inc. acquired a new stake in Johnson & Johnson in the second quarter worth about $71,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Scotiabank assumed coverage on shares of Johnson & Johnson in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price objective for the company. Citigroup raised their price target on shares of Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a report on Thursday. Barclays boosted their price objective on shares of Johnson & Johnson from $176.00 to $197.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Wells Fargo & Company boosted their price target on Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Guggenheim raised their price objective on Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $207.55.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $211.65 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock has a market capitalization of $509.93 billion, a price-to-earnings ratio of 20.43, a PEG ratio of 2.36 and a beta of 0.36. The firm’s 50 day simple moving average is $196.09 and its 200-day simple moving average is $177.42. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $212.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion for the quarter. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.